[go: up one dir, main page]

NO952987L - Wound healing mixture - Google Patents

Wound healing mixture

Info

Publication number
NO952987L
NO952987L NO952987A NO952987A NO952987L NO 952987 L NO952987 L NO 952987L NO 952987 A NO952987 A NO 952987A NO 952987 A NO952987 A NO 952987A NO 952987 L NO952987 L NO 952987L
Authority
NO
Norway
Prior art keywords
wound healing
healing mixture
growth factor
insulin
mixture
Prior art date
Application number
NO952987A
Other languages
Norwegian (no)
Other versions
NO952987D0 (en
Inventor
George N Cox
Thomas A Mustoe
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of NO952987D0 publication Critical patent/NO952987D0/en
Publication of NO952987L publication Critical patent/NO952987L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasøytisk sårhelingsblanding blir tilveiebragt som omfatter insulinlignende vekstfaktor - l i kom- binasjon med insulinlignende vekstfaktorbindende protein. De farmasøytiske blandinger er formulert for ikkc-systematisk administrering. En foreliggende oppfinnelse tilveiebringer fremgangsmåter til å bruke sårhelende blandinger.Pharmaceutical wound healing composition is provided which comprises insulin-like growth factor-1 in combination with insulin-like growth factor-binding protein. The pharmaceutical compositions are formulated for non-systematic administration. The present invention provides methods for using wound healing compositions.

NO952987A 1993-01-29 1995-07-27 Wound healing mixture NO952987L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1103193A 1993-01-29 1993-01-29
PCT/US1994/000799 WO1994016723A2 (en) 1993-01-29 1994-01-25 Wound healing composition

Publications (2)

Publication Number Publication Date
NO952987D0 NO952987D0 (en) 1995-07-27
NO952987L true NO952987L (en) 1995-08-30

Family

ID=21748560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952987A NO952987L (en) 1993-01-29 1995-07-27 Wound healing mixture

Country Status (8)

Country Link
EP (1) EP0686040A1 (en)
JP (1) JPH09500088A (en)
KR (1) KR960700069A (en)
AU (1) AU6093794A (en)
CA (1) CA2154078A1 (en)
FI (1) FI953615A7 (en)
NO (1) NO952987L (en)
WO (1) WO1994016723A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
PT871730E (en) * 1995-10-11 2004-11-30 Chiron Corp COMBINATION OF PDGF, KGF, IGF AND IGFBP FOR WOUND HEALING
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
DE60133271T2 (en) 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco TREATMENT OF CORDIAL DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68923556T2 (en) * 1988-07-15 1996-04-11 Central Sydnry Area Health Ser ACID-SENSITIVE SUB-UNIT OF AN INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEX.
ATE208816T1 (en) * 1990-08-28 2001-11-15 Chiron Corp NEW INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN IGFBP-5
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
ATE215835T1 (en) * 1992-08-26 2002-04-15 Celtrix Pharma METHOD FOR SYSTEMIC TREATMENT OF CATABOLIC CONDITIONS AND SYSTEMIC TISSUE DAMAGE

Also Published As

Publication number Publication date
NO952987D0 (en) 1995-07-27
AU6093794A (en) 1994-08-15
EP0686040A1 (en) 1995-12-13
JPH09500088A (en) 1997-01-07
KR960700069A (en) 1996-01-19
CA2154078A1 (en) 1994-08-04
WO1994016723A3 (en) 1994-09-15
FI953615A0 (en) 1995-07-28
FI953615L (en) 1995-07-28
WO1994016723A2 (en) 1994-08-04
FI953615A7 (en) 1995-07-28

Similar Documents

Publication Publication Date Title
NO971889L (en) Compounds and compositions for delivery of active agents
UA42747C2 (en) PEPTIDE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD FOR STIMULATING GROWTH HORMONE SECRETION
AU5431390A (en) Novel arylpyridazines, their manufacture, use and medicaments containing them
NO962286D0 (en) N-substituted azabicycloalkane derivatives such as neuroleptics etc.
NO20061455L (en) 2.6 dioxopiperidine and pharmaceutical preparations containing them
ATE383169T1 (en) COMPONENT AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
PT758248E (en) FORMULATIONS FOR THE FACTOR IX
FI960727A0 (en) Heterocycles useful as neurokinin antagonists
CY1108110T1 (en) FACTORS AND METHODS FOR PROTECTION, TREATMENT AND CORRUPTION
NO971568L (en) Keratinocyte growth factor analogues
ATE311373T1 (en) OXADIAZOLE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS
DK0888323T3 (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
BR9910329A (en) Compound, pharmaceutical composition, process to stimulate the release of growth hormone from a mammal's pituitary, and use of a compound
ES2139081T3 (en) PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE HUMAN HORMONE OF GROWTH.
NO952987L (en) Wound healing mixture
DK0556322T3 (en) Aminosulfonylurinstof-ACAT inhibitors
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
NO962285L (en) N-substituted azabicycloheptane derivatives used, for example, as neuroleptics
AR020832A1 (en) PROCEDURE FOR THE PREPARATION OF A HIGH PURITY COMPOSITION OF (7ALFA, 17ALFA) -17-HIDROXI-7-METIL-19-NOR-17-PREGN-5- (10) -EN-20-IN-3-ONA
CA2201944A1 (en) Analogs of keratinocyte growth factor having enhanced temperature stability
SE9504662D0 (en) New compounds
EP1074264A4 (en) Neovascularization inhibitors
ATE227122T1 (en) STABILIZED TABLET FORMULATION
BR9906975A (en) Compound, use of it, pharmaceutical composition, and process to stimulate the release of growth hormone by the pituitary of a mammal
AU6646094A (en) New pyridinium salts and their use for controlling helicobacter bacteria